Biophytis (EPA:ALBPS) | WebDisclosure

REGULATED PRESS RELEASE

published on 05/14/2024 at 07:00, 2 years 4 months ago

Biophytis annonce le design de son étude clinique de phase 2 OBA dans l'obésité
Biophytis annonce le design de son étude clinique de phase 2 OBA dans l'obésité avec BIO101 (20-hydroxyecdysone), visant à évaluer l'efficacité et la sécurité chez des patients obèses sous GLP-1 RAs

Biophytis Étude Clinique BIO101 Obésité Phase 2 OBA
REGULATED PRESS RELEASE

published on 05/14/2024 at 07:00, 2 years 4 months ago

Biophytis announces the design of its phase 2 OBA clinical study in obesity
Biophytis announces the design of its phase 2 OBA clinical study in obesity with BIO101 (20-hydroxyecdysone), aiming to test efficacy and safety for muscle function in obese patients. Study to start mid-2024 with results expected in 2025

Biophytis BIO101 Obesity Phase 2 OBA Clinical Study Muscle Function
BRIEF

published on 04/29/2024 at 14:44, 2 years 4 months ago

Biophytis annonce le déploiement de sa stratégie de partenariat dans le secteur de l'obésité

Biophytis Partenariats Stratégiques Pharmaceutique BIO101 Obésité
BRIEF

published on 04/29/2024 at 14:44, 2 years 4 months ago

Biophytis announces the deployment of its partnership strategy in the obesity sector

Strategic Partnerships Biophytis Pharmaceutical BIO101 Obesity
PRESS RELEASE

published on 04/29/2024 at 14:39, 2 years 4 months ago

Biophytis déploie sa stratégie de partenariat dans le domaine de l’obésité
Biophytis annonce le déploiement de sa stratégie de partenariat dans le domaine de l’obésité, visant des collaborations pour le développement de traitements novateurs

Stratégie Biophytis Partenariat Obésité Traitements
PRESS RELEASE

published on 04/29/2024 at 14:39, 2 years 4 months ago

Biophytis is deploying its partnership strategy in obesity
Biophytis announces the implementation of a dedicated partnership strategy in obesity, aiming to collaborate with global pharmaceutical companies for drug development and commercialization. CEO Stanislas Veillet emphasizes the importance of addressing the obesity medical challenge through partnerships

Biophytis Drug Development Obesity Partnership Strategy Pharmaceutical Companies
BRIEF

published on 04/29/2024 at 07:05, 2 years 4 months ago

Biophytis élargit ses horizons dans le secteur de l'obésité avec une nouvelle stratégie de partenariat

Biophytis Développement Clinique BIO101 Obésité Partenariats Pharmaceutiques
BRIEF

published on 04/29/2024 at 07:05, 2 years 4 months ago

Biophytis Advances Partnership Strategy in Obesity Sector

Biophytis Obesity Treatment Healthcare Innovation Pharmaceutical Partnerships BIO101
REGULATED PRESS RELEASE

published on 04/29/2024 at 07:00, 2 years 4 months ago

Biophytis déploie sa stratégie de partenariat dans le domaine de l’obésité
Biophytis déploie une stratégie de partenariat dans le domaine de l’obésité pour le développement de traitements révolutionnaires. La société recherche des partenaires pour licencier son candidat-médicament BIO101

Biophytis Partenariat Développement Clinique Obésité Candidat-médicament
REGULATED PRESS RELEASE

published on 04/29/2024 at 07:00, 2 years 4 months ago

Biophytis is deploying its partnership strategy in obesity
Biophytis announces partnership strategy for obesity, aiming to license out drug candidate BI0101 to global pharma companies for development, launch, and commercialization. CEO stresses importance of partnering for medical innovation

Biophytis Medical Innovation Obesity Partnership Strategy Drug Candidate

Published on 09/23/2026 at 18:25, 23 minutes ago

Boba Mint Holdings Ltd. Reports Strong Early Subscription Adoption Following Soft Launch of Amino Pro
Published on 09/23/2026 at 15:42, 3 hours 6 minutes ago

Global Atomic Announces C$50 Million Public Offering of Units
Published on 09/23/2026 at 14:31, 4 hours 17 minutes ago

First Breach Completes First Untethered Flight of Proprietary Drone Prototype, Advancing American-Made Unmanned Systems Program
Published on 09/23/2026 at 14:30, 4 hours 18 minutes ago

Phase II Clinical Trial of NV-387 as a Treatment for Monkeypox (MPox) Has Begun in DRC, Announces NanoViricides
Published on 09/23/2026 at 14:00, 4 hours 48 minutes ago

Integrated Rewards Launches "Celebrate Canadian" Campaign to Connect Canadian Brands with Millions of Consumers

View all ACCESSWIRE

Published on 09/23/2026 at 18:05, 42 minutes ago

XPRIZE Wildfire Awards $4.55M to Innovators Advancing Wildfire Detection and Response
Published on 09/23/2026 at 18:00, 47 minutes ago

ARVERNE GROUP: Release of the 2026 half-year financial report
Published on 09/23/2026 at 18:00, 47 minutes ago

ARVERNE GROUP: Mise à disposition du rapport financier semestriel 2026
Published on 09/23/2026 at 18:00, 47 minutes ago

ARVERNE GROUP: Premier semestre 2026 Croissance de 60,1 % du volume d’activité brut, à 16,8 M€ Des performances opérationnelles supérieures aux attentes
Published on 09/23/2026 at 18:00, 47 minutes ago

MHM CORPORATE ANNONCE LE SUCCÈS DE SON AUGMENTATION DE CAPITAL AVEC MAINTIEN DU DROIT PREFERENTIEL DE SOUSCRIPTION AINSI QU’UN REMBOURSEMENT PARTIEL D’OBLIGATIONS REMBOURSABLES EN ACTIONS

View all EQS

Published on 09/23/2026 at 18:00, 48 minutes ago

CIS : H1 2026 results.
Published on 09/23/2026 at 18:00, 48 minutes ago

SMTPC - Communiqué sur les résultats du 1er semestre 2026
Published on 09/23/2026 at 18:00, 48 minutes ago

CIS : Résultats semestriels 2026.
Published on 09/23/2026 at 18:00, 48 minutes ago

SMTPC - Rapport financier du 1er semestre 2026
Published on 09/23/2026 at 17:45, 1 hour 3 minutes ago

Report on share repurchases from 16 to 21 September 2026

View all LES ECHOS COMFI WIRE

News